Taft Chicago partner Roshan Shrestha is quoted in the Law360 article “Senate Bill Not Seen As Death Knell For Skinny Label Suits.” The article discusses a Senate bill that aims to protect generic-drug makers from patent suits when using so-called skinny labels. The full article is here (subscription required).

Shrestha focuses his practice on intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts. He has broad litigation experience, including district court litigation, contested AIA proceedings, e.g., Re-examination and Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB) in the United States Patent and Trademark Office (USPTO), International Trade Commission (ITC), and appellate matters.